INTRODUCTION: Tubulocystic renal carcinoma (TCRC) is a recently described neoplastic entity. To date, clinicopathological features on less than hundred cases of these rare tumours have been characterized exclusively in the pathological literature. Herein, we present five additional cases emphasizing clinical aspects on these rare renal neoplasms. MATERIAL AND METHOD: Cases diagnosed as TCRC were retrieved and reviewed from the routine and consultation files of the Pilsen tumour registry comprising over 20,000 cases of renal tumours. RESULTS: All patients were men, mean age 56 years (range 29-70). Features on computed tomography (CT) were in two cases Bosniak III, one IV and two were solid tumours. In four patients, nephrectomy was performed, and one patient underwent resection. At the time of surgery, two patients had metastases. In one case, both primary tumour and metastases were active on FDG positron emission tomography (PET)/CT. Both patients with metastatic disease were treated with sunitinib with partial response. One patient died 26 months postoperatively and the other patient is alive 5 months after surgery. Three patients with localized tumours are without evidence of disease 31, 28 and 7 months after surgery. In one case, the resected tumour was histologically combined with a papillary renal cell carcinoma (PRCC). CONCLUSION: TCRC occurs predominantly in men with a wide age range. TCRC frequently displays a cystic component which may render a radiological classification of Bosniak III or IV. FDG PET/CT is helpful in the detection of metastases. TCRC has definitive malignant potential. Our findings support a possible relationship to PRCC. The tyrosine kinase inhibitor sunitinib may be used a therapeutical agent with partial response and temporary effect.

Department of Urology Charles University Hospital E Beneše 13 305 99 Plzeň Czech Republic

Zobrazit více v PubMed

Am J Surg Pathol. 2009 Jul;33(7):1103-6 PubMed

Eur J Cancer. 2009 Jan;45(2):228-47 PubMed

Clin Lab Med. 2005 Jun;25(2):393-416 PubMed

Am J Surg Pathol. 2009 Mar;33(3):384-92 PubMed

Urology. 1997 Nov;50(5):679-84 PubMed

Histopathology. 2002 Dec;41(6):549-55 PubMed

Adv Anat Pathol. 2010 May;17(3):209-14 PubMed

Eur Urol. 2009 Jul;56(1):e3 PubMed

Am J Surg Pathol. 2009 Dec;33(12):1840-9 PubMed

Mod Pathol. 2009 Jun;22 Suppl 2:S2-S23 PubMed

Int Urol Nephrol. 2005;37(4):743-50 PubMed

ScientificWorldJournal. 2010 Apr 01;10:586-9 PubMed

Virchows Arch. 2007 Nov;451(5):905-9 PubMed

South Med J. 2009 Jul;102(7):754-7 PubMed

Ann Oncol. 2008 Sep;19(9):1655-6 PubMed

Anticancer Res. 2010 Feb;30(2):641-4 PubMed

Actas Urol Esp. 2004 Jun;28(6):478-83 PubMed

Am J Surg Pathol. 2008 Feb;32(2):177-87 PubMed

Urology. 2005 Sep;66(3):484-8 PubMed

Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant

Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases